Mark J. Golden, FASAE, CAE, will step down as chief executive officer of the Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) when his contract concludes on August 17.
“ADLM applauds the U.S. District Court for the Eastern District of Texas for issuing a decision to vacate the Food and Drug Administration’s (FDA’s) final rule to regulate laboratory developed tests as medical devices. The court found that the FDA rule would have negatively impacted testing on which patients and clinicians depend, and that the rule also went against Congress’ intent, which is for laboratory services to be regulated under the current framework administered by the Centers for Medicare & Medicaid Services (CMS).
Adult antibody thresholds are currently used to determine whether immunocompromised children should get a measles, mumps, and rubella (MMR) booster shot. However, a new study shows that these thresholds fail to identify a significant percentage of children who need to be revaccinated. These findings, published today in the Association for Diagnostics & Laboratory Medicine’s (formerly AACC’s) Clinical Chemistry journal, could help to ensure that immunocompromised children are protected from these viruses — which is especially important now that measles in particular could be experiencing a revival.
The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) is pleased to announce that Dr. Ian Young will assume the position of editor in chief for ADLM’s The Journal of Applied Laboratory Medicine, effective January 1, 2026.
The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) released a position statement today emphasizing that limited access to quality clinical laboratory services is impeding children’s health, and that action must be taken to address this significant problem.
Laboratory developed tests play an essential role in diagnosing and treating many of the conditions that affect pediatric patients. Join the Association for Diagnostics & Laboratory Medicine (formerly AACC), the Children’s Hospital Association, and leading experts in laboratory medicine and pediatric health for a discussion about the use of laboratory developed tests in pediatric care, and a duplicative rule issued by the Food and Drug Administration (FDA) that threatens access to these vital tests.
WASHINGTON — A new study in the Association for Diagnostics & Laboratory Medicine’s (ADLM’s, formerly AACC’s) The Journal of Applied Laboratory Medicine (JALM) found that a simplified version of the standard screening method for identifying heparin-induced thrombocytopenia (HIT) — a dangerous side effect of the blood thinner heparin — did a better job than the full technique of identifying which patients had the condition.
Diagnostic stewardship brings together healthcare professionals across specialties to ensure patients get the right clinical laboratory tests at the right time. This special issue of the Association for Diagnostics & Laboratory Medicine’s (ADLM’s, formerly AACC’s) The Journal of Applied Laboratory Medicine highlights the invaluable role that diagnostic stewardship plays in reducing medical errors, managing costs, and optimizing the effectiveness of patient care. What’s more, the issue was designed by just such a wide-ranging group of experts.
The use of genomic testing in clinical practice, once thought to be a distant goal, is now a reality that is profoundly impacting medicine. This special issue of the Association for Diagnostics & Laboratory Medicine’s (ADLM’s, formerly AACC’s) Clinical Chemistry journal spotlights the breaking research from laboratory medicine experts that is driving this field forward — and that is set to transform diagnosis and care for medical conditions across the board.
A novel study published today in ADLM’s journal, Clinical Chemistry, has found that it takes the human body much longer than previously thought to clear xylazine — one of the most popular emerging drugs of abuse in the U.S. This much-needed insight into how the body processes xylazine could improve treatment of overdose patients who’ve taken it.
The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) released a position statement today supporting consumers’ efforts to play active roles in their healthcare by ordering their own laboratory tests. The statement emphasizes that such direct-to-consumer testing should be performed only by reputable laboratories that are certified under the Clinical Laboratory Improvement Amendments (CLIA) and that are committed to providing clear information and guidance to help consumers interpret the results.
Today, the Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC), together with the American Association of Bioanalysts, American Society for Clinical Pathology, American Society for Microbiology, and the Infectious Disease Society of America, has filed an amicus brief in the case of American Clinical Laboratory Association (ACLA), et al. v. U.S. Food and Drug Administration (FDA), et al.
Today, the Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) released the latest results from an ongoing survey that ADLM has been conducting to determine how the Food and Drug Administration’s (FDA’s) final laboratory developed tests rule will impact patient care. The survey found that, under the FDA rule, individuals from rural and historically marginalized communities will have severely limited access to vital tests, which could lead to harmful and even life-threatening delays in diagnosis and treatment.
The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) has issued expert guidance on lipid tests, which measure blood levels of fats and cholesterol to help assess a patient’s risk of heart disease and stroke. By giving clinicians and laboratory medicine professionals much-needed clarity on how to best use these tests, the new guidelines will ensure that more patients with cardiovascular disease get the treatment they need.
The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC), welcomed thousands of laboratory experts to ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo) from July 28-August 1. The meeting featured groundbreaking advances in diagnostic research and technology that exemplify the essential role that the field of laboratory medicine plays in patient care.
Exciting research at the frontier of artificial intelligence and data science in laboratory medicine was presented today at ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo).
Today at ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo), researchers will present data on a novel test that predicts whether Alzheimer’s patients are genetically predisposed to side effects from anti-amyloid drugs, a promising new class of Alzheimer’s therapeutics.
Breaking research shows that rates of cannabis use during pregnancy are far higher than previously thought, a finding that could improve efforts to identify pregnant cannabis users and inform them of potential risks.
In a new study, researchers have demonstrated that there is an insufficient basis for incorporating race in prenatal screening for birth defects. In a second, separate study, researchers have found that HIV-exposed uninfected children are at higher risk for health problems compared to uninfected, unexposed children.
The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) is pleased to announce the recipients of its 2024 Top Corporate Supporter Award, a distinction given to companies and organizations that generously support the association through advertising, sponsorships, and exhibits.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right